Alembic Pharmaceuticals has received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, used to treat post-surgery eye inflammation and anterior uveitis, further strengthening its US generics portfolio.
.png "Sun Pharma focuses on US innovation amid generics slowdown")
Sun Pharma is working to stabilize its US generics business as manufacturing issues ease, while pushing innovation-led growth, specialty launches, and preparing for the day-one launch of generic semaglutide in India.
Pharma stocks are soaring after the Budget 2026 announcement of a Rs 10,000 crore biopharma push. This move under the Biopharma Shakti initiative is set to strengthen India's role in global healthcare, driving investment and innovation.
Biocon Biologics has secured a credit rating upgrade from S&P Global Ratings to BB+, reflecting a simpler capital structure, improved financial discipline, and steady growth outlook in the global biosimilars market.
In a first-of-its-kind initiative, Gleneagles Hospital has introduced an AI-enabled Hub-and-Spoke stroke model that connects diagnostic centers across Mumbai and Navi Mumbai to its stroke team in real time, helping detect strokes early, reduce...
BPL Medical Technologies made a strong impact at the 78th Annual Conference of the diagnostics, and women’s health technologies...
The Centre has fixed minimum import prices (MIP) for select antibiotic raw materials to curb low-priced imports and support bulk drug manufacturing in the country. The move, notified by the Directorate General of Foreign Trade (DGFT) through a DGF...
Piramal Pharma said it is seeing early signs of recovery in its CDMO business, driven by higher RFP activity and improving US biotech funding, even as inventory destocking continued to weigh on Q3FY26 results.c
Natural Remedies shines at IPPE 2026, showcasing its science-backed phytogenics like NR-SBP. Their focus on sustainability, animal care, and productivity sets a new industry standard.
.png "AstraZeneca to Invest $15B in China Through 2030 Expansion Plan")
AstraZeneca announced a $15 billion investment in China through 2030 to expand R&D, manufacturing, and advanced therapies, strengthening China-UK healthcare collaboration and delivering next-generation treatments worldwide.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")